Skip to main content

Advertisement

Table 2 Clinical trials using proteomic analysis

From: Genomic and proteomic approaches for studying human cancer: Prospects for true patient-tailored therapy

Sponsor Principal investigator, centre Disease, application
NCI Elise Kohn, Warren Grant Magnuson Clinical Center, NIH, Bethesda, MD, USA Ovarian cancer, developing serum proteomic profile associated with first clinical response
NCI Elise Kohn, Warren Grant Magnuson Clinical Center, NIH, Bethesda, MD, USA Breast and ovarian cancer, protein microarray to assess response to EGFR inhibitors and Gleevac
NCI Susan Bates, Warren Grant Magnuson Clinical Center, NIH, Bethesda, MD, USA Breast and ovarian cancer, protein microarray to assess response to Herceptin/Taxol combination therapy
NCI Sam Hwang, Warren Grant Magnuson Clinical Center, NIH, Bethesda, MD, USA Inflammatory and neoplastic skin diseases, developing serum proteomic profile for diagnosis
NCI Michael Solomon, Warren Grant Magnuson Clinical Center, NIH, Bethesda, MD, USA Cardiac disease, developing serum proteomic profile for diagnosis of acute cardiac allograft rejection
NCI Mahrukh Hussain, Warren Grant Magnuson Clinical Center, NIH, Bethesda, MD, USA Ovarian cancer, developing serum proteomic profile associated with relapse
  1. Abbreviations: EGFR, epidermal growth factor receptor